MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
Aptevo Therapeutics Revenue 2011-2026 | APVO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Aptevo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 3.11 M | 12.3 M | 4.31 M | 32.4 M | 23.1 M | 14.7 M | 36.4 M | 33.6 M | 45.6 M | 170 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.6 M | 170 K | 20.6 M |
Quarterly Revenue Aptevo Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | 3.11 M | 3.11 M | 3.11 M | - | 3.1 M | 3.11 M | 2.42 M | - | 1.46 M | 473 K | - | - | 9.01 M | 7.36 M | 7.02 M | - | 5.82 M | 6.83 M | 4.07 M | - | 6.17 M | 10.8 M | 2.14 M | 8.77 M | 2.82 M | 10.2 M | 8.07 M | 8.29 M | 6.56 M | 7.09 M | 11.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.7 M | 473 K | 5.7 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.88 | -1.69 % | $ 6.47 M | China |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Aquestive Therapeutics
AQST
|
44.5 M | $ 4.1 | 1.23 % | $ 438 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
958 M | $ 22.45 | 1.13 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
58.7 B | - | - | $ 96.9 B | Britain |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
31.1 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
32.2 M | - | - | $ 3.74 B | USA |
 |
Cerus Corporation
CERS
|
234 M | $ 2.03 | 5.73 % | $ 387 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
1 M | - | -16.75 % | $ 25.8 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
1.07 M | $ 13.64 | 9.82 % | $ 1.81 B |  Australia |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M |  Canada |
 |
BioNTech SE
BNTX
|
482 M | $ 103.45 | 1.85 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
163 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
9 M | $ 1.44 | -3.36 % | $ 235 M | France |
 |
Dynavax Technologies Corporation
DVAX
|
277 M | - | - | $ 2.02 B | USA |
 |
Editas Medicine
EDIT
|
40.5 M | $ 3.0 | 6.38 % | $ 266 M | USA |
 |
Edesa Biotech
EDSA
|
329 K | $ 18.27 | 14.94 % | $ 58.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 3.19 | 6.69 % | $ 5.25 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
15.8 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
75 K | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
9.99 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |